These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22076550)

  • 61. Anti-PGL1 salivary IgA/IgM, serum IgG/IgM, and nasal Mycobacterium leprae DNA in individuals with household contact with leprosy.
    Brito e Cabral P; Júnior JE; de Macedo AC; Alves AR; Gonçalves TB; Brito e Cabral TC; Gondim AP; Pinto MI; Oseki KT; Camara LM; Rabenhorst SH; Nagao-Dias AT
    Int J Infect Dis; 2013 Nov; 17(11):e1005-10. PubMed ID: 23871279
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Do human leukocyte antigens have a role to play in differential manifestation of multibacillary leprosy: a study on multibacillary leprosy patients from north India.
    Rani R; Zaheer SA; Mukherjee R
    Tissue Antigens; 1992 Sep; 40(3):124-7. PubMed ID: 1440566
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Leprosy serology (ML Flow test) in borderline leprosy patients classified as paucibacillary by counting cutaneous lesions: an useful tool.
    Barreto JA; Nogueira ME; Diorio SM; Bührer-Sékula S
    Rev Soc Bras Med Trop; 2008; 41 Suppl 2():45-7. PubMed ID: 19618075
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Is PGL-1 also present in Leishmania donovani promastigotes?
    Gupta PN; Pal NK
    Indian J Lepr; 1998; 70(2):161-4. PubMed ID: 9724851
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Major proteins of mycobacterial strain ICRC and Mycobacterium leprae, identified by antibodies in sera from leprosy patients and their contacts.
    Chiplunkar SV; Kudalkar JL; Butlin R; Samson PD; Deo MG; Gangal SG
    J Clin Microbiol; 1992 Feb; 30(2):336-41. PubMed ID: 1537902
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Changes in cellular response to mycobacterial antigens and cytokine production patterns in leprosy patients during multiple drug therapy.
    Trao VT; Huong PL; Thuan AT; Anh DD; Trach DD; Rook GA; Wright EP
    Immunology; 1998 Jun; 94(2):197-206. PubMed ID: 9741341
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term culture of multibacillary leprosy macrophages isolated from skin lesions: a new model to study Mycobacterium leprae-human cell interaction.
    Moura DF; Teles RM; Ribeiro-Carvalho MM; Teles RB; Santos IM; Ferreira H; Fulco TO; Nery JA; Sampaio EP; Sarno EN
    Br J Dermatol; 2007 Aug; 157(2):273-83. PubMed ID: 17553031
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cytokines as biomarkers to monitoring the impact of multidrug therapy in immune response of leprosy patients.
    Cassirer-Costa F; Medeiros NI; Chaves AT; Lyon S; Coelho-Dos-Reis JGA; Ribeiro-Junior AF; Correa-Oliveira R; Rocha MOC; Gomes JAS
    Cytokine; 2017 Sep; 97():42-48. PubMed ID: 28570932
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Immunoglobulin class specific antibodies to M. leprae in leprosy patients, including the indeterminate group and healthy contacts as a step in the development of methods for sero-diagnosis of leprosy.
    Melsom R; Harboe M; Myrvang B; Godal T; Belehu A
    Clin Exp Immunol; 1982 Feb; 47(2):225-33. PubMed ID: 7042137
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Class-specific immunoglobulins and antibodies to mycobacterial sonicates and autoantigens in leprosy patients and contacts.
    Mathew JM; Muthukkaruppan V
    Microb Pathog; 1993 Nov; 15(5):367-76. PubMed ID: 8015417
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Interplay among differential exposure to
    Cunha EHM; Marçal PHF; Gama RS; de Oliveira LBP; Pinheiro RO; Sarno EN; Brito-de-Sousa JP; de Souza MLM; Fairley JK; Valente TNS; Velloso-Rodrigues C; Martins-Filho OA; de Oliveira DR; Fraga LAO
    Front Immunol; 2023; 14():1130137. PubMed ID: 37187734
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Suppression of delayed hypersensitivity skin reactions to tuberculin by M. leprae antigens in patients with lepromatous and tuberculoid leprosy.
    Sengupta U; Sinha S; Ramu G; Lamb J; Ivanyi J
    Clin Exp Immunol; 1987 Apr; 68(1):58-64. PubMed ID: 3308210
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Identifying Leprosy and Those at Risk of Developing Leprosy by Detection of Antibodies against LID-1 and LID-NDO.
    Amorim FM; Nobre ML; Ferreira LC; Nascimento LS; Miranda AM; Monteiro GR; Dupnik KM; Duthie MS; Reed SG; Jeronimo SM
    PLoS Negl Trop Dis; 2016 Sep; 10(9):e0004934. PubMed ID: 27658042
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Production of host-protective (IFN-gamma), host-impairing (IL-10, IL-13) and inflammatory (TNF-alpha) cytokines by PBMC from leprosy patients stimulated with mycobacterial antigens.
    Machado P; Abrams J; Santos S; Brennan P; Barral A; Barral-Netto M
    Eur J Dermatol; 1998 Mar; 8(2):98-103. PubMed ID: 9649657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Limiting dilution analysis in leprosy.
    Mullins RJ; Roche P; Adams E; Jones P; Chen S; Theuvenet W; Basten A
    Immunol Cell Biol; 1992 Aug; 70 ( Pt 4)():277-90. PubMed ID: 1427986
    [TBL] [Abstract][Full Text] [Related]  

  • 76. IgG subclass distribution of antibody responses to protein and polysaccharide mycobacterial antigens in leprosy and tuberculosis patients.
    Sousa AO; Henry S; Marója FM; Lee FK; Brum L; Singh M; Lagrange PH; Aucouturier P
    Clin Exp Immunol; 1998 Jan; 111(1):48-55. PubMed ID: 9472660
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Experience and lessons from the use of lepromin and Mycobacterium leprae-specific serology.
    Sengupta U
    Lepr Rev; 2000 Dec; 71 Suppl():S63-6. PubMed ID: 11201890
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Production of transforming growth factor-beta 1 (TGF-beta1) by blood monocytes from patients with different clinical forms of leprosy.
    Goulart IM; Mineo JR; Foss NT
    Clin Exp Immunol; 2000 Dec; 122(3):330-4. PubMed ID: 11122237
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Assessment of the immune deficit in leprosy patients and the effect of recombinant IL-2 in vitro.
    Locniskar M; McEniry DW; Mudd DW; Rose P; Lucas DC; Larrick J; McAdam KP
    Int J Lepr Other Mycobact Dis; 1987 Jun; 55(2):249-60. PubMed ID: 3298472
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antibodies to a synthetic analog of phenolic glycolipid-I of Mycobacterium leprae in healthy household contacts of patients with leprosy.
    Menzel S; Harboe M; Bergsvik H; Brennan PJ
    Int J Lepr Other Mycobact Dis; 1987 Dec; 55(4):617-25. PubMed ID: 3323365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.